Forgot password


** IMPORTANT - PLEASE READ THIS!! **


  • To complete registration, your 2024 dues must be paid.
  • If you have paid your 2024 dues and you are having trouble registering for an event, please login with your email address and password and attempt to register again.
  • If you continue to have registration trouble, please send an email to Brian Ellis (bellis@kcvma.com). 


January CE

  • Thursday, January 28, 2021
  • 7:00 PM - 9:00 PM
  • Online
  • 119

Registration

Registration is closed
Speaker:

Lindsay M.VanHusan, DVM
Topic:

A case based approach to understanding canine chronic enteropathy (CE)/inflammatory bowel disease (IBD) (distance interactive)

Date: January 28, 2021
Time: 7pm
Location: Online (Link will be provided at a later date)
CE: TBA
Fee: No fee to attend this event, but RSVP is required by January 25th. Current membership dues cover all CE.
About: The diagnostic approach to defining canine chronic enteropathy (CE) will be discussed. Changes in small animal gastroenterology terminology will be reviewed. Chronic enteropathy is defined as the presence of gastrointestinal signs of a minimum of 3 weeks’ duration, where the clinician has excluded all extra-intestinal and all primary intestinal disease (bacterial, fungal, parasitic, neoplastic and structural) as the cause for the symptoms. The etiology and pathophysiology of canine chronic enteropathy will be reviewed. Given that CE is a diagnosis of exclusion we will outline the extensive work up that would be required for a clinician to reach this conclusion.  We will talk about specific non-invasive diagnostic tests for chronic enteropathy and their potential diagnostic, prognostic and therapeutic utility. We will talk about a relatively new test panel for CE/IBD assessing the level of IgA antibodies (CE/IBD biomarkers) against 3 different targets (Anti-OmpC Porin surface antigen (ACA), Anti-canine calprotectin (ACNA), Anti-Gliadin(AGA)) and this panels ability to identify a case consistent with IBD, along with the panels potential to guide therapeutic decision maker, and its possible use in monitoring treatment response. Clinical cases will be discussed to illustrate the application and interpretation of the CE assay results. Commonly asked questions to CE/IBD will be reviewed in closing.


© Kansas City Veterinary Medical Association
Powered by Wild Apricot Membership Software